Financial Comparison: Envoy Medical (NASDAQ:COCH) and Lifeward (NASDAQ:LFWD)

Lifeward (NASDAQ:LFWD) and Envoy Medical (NASDAQ:COCH) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, risk, valuation, profitability, analyst recommendations, institutional ownership and dividends.

Institutional & Insider Ownership

26.8% of Lifeward shares are owned by institutional investors. Comparatively, 8.6% of Envoy Medical shares are owned by institutional investors. 1.1% of Lifeward shares are owned by company insiders. Comparatively, 7.2% of Envoy Medical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Lifeward and Envoy Medical, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lifeward	1	1	2	0	2.25
Envoy Medical	1	1	2	0	2.25

Lifeward presently has a consensus target price of $10.00, suggesting a potential upside of 68.35%. Envoy Medical has a consensus target price of $21.00, suggesting a potential upside of 195.77%. Given Envoy Medical’s higher possible upside, analysts plainly believe Envoy Medical is more favorable than Lifeward.

Profitability

This table compares Lifeward and Envoy Medical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Lifeward	-141.28%	-235.86%	-81.72%
Envoy Medical	-11,304.83%	N/A	-144.13%

Volatility and Risk

Lifeward has a beta of 0.55, suggesting that its stock price is 45% less volatile than the S&P 500. Comparatively, Envoy Medical has a beta of 2.03, suggesting that its stock price is 103% more volatile than the S&P 500.

Valuation and Earnings

This table compares Lifeward and Envoy Medical”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lifeward	$22.03 million	0.76	-$19.91 million	($16.82)	-0.35
Envoy Medical	$240,000.00	228.38	-$23.76 million	($4.60)	-1.54

Lifeward has higher revenue and earnings than Envoy Medical. Envoy Medical is trading at a lower price-to-earnings ratio than Lifeward, indicating that it is currently the more affordable of the two stocks.

Summary

Envoy Medical beats Lifeward on 6 of the 11 factors compared between the two stocks.

About Lifeward

ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes technologies that enable mobility and wellness in rehabilitation and daily life for individuals with physical and neurological conditions in the United States, Europe, the Asia-Pacific, and internationally. It offers ReWalk personal exoskeleton and rehabilitation exoskeleton devices; ReStore, a soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke; AlterG Anti-Gravity System for use in physical and neurological rehabilitation and athletic training; MyoCycle devices; and ReBoot, a personal soft exo-suit for home and community use by individuals post-stroke. The company markets and sells its products directly to institutions and individuals, as well as through third-party distributors. The company was formerly known as Argo Medical Technologies Ltd. ReWalk Robotics Ltd. was incorporated in 2001 and is headquartered in Yokneam Illit, Israel.

About Envoy Medical

Envoy Medical, Inc., a hearing health company, provides medical technologies for the hearing loss spectrum. Its products include personal sound amplification devices; hearing aids; Esteem fully implanted active middle ear implants; auditory osseointegrated implants; and Acclaim cochlear implants. The company was formerly known as Envoy Medical Corporation and changed its name to Envoy Medical, Inc. in September 2023. Envoy Medical, Inc. was founded in 1995 and is headquartered in White Bear Lake, Minnesota.